Early Clinical Trial Shows Drug Activity to Work in Patients with Acral and Mucosal Melanoma
Results of a Phase 1/2 clinical trial showed promising data for patients with advanced acral and mucosal melanoma. The results…
Melanoma Research
06/05/2025
Early Clinical Trial Shows Drug Activity to Work in Patients with Acral and Mucosal Melanoma
Results of a Phase 1/2 clinical trial showed promising data for patients with advanced acral and mucosal melanoma. The results…
|
06/05/2025
Results Prove Immunotherapy Should be the Initial Treatment for BRAF Mutant Tumors
Five-year clinical trial results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirmed…
|
06/03/2025
Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence
We usually don’t feature nonmelanoma skin cancer articles here, but we thought you might be interested in what’s happening in…
|
05/28/2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
|
|
05/09/2025
Tri-State Melanoma Consortium – Inaugural Convening
Last night, leading melanoma researchers and clinicians from across the New York , New Jersey, and Connecticut region gathered at…
|
04/24/2025
Genetic Testing Performed in Melanoma
A Q&A with an Investigator at the National Institutes of Health Dr. Michael Sargen M.D. is an Assistant Clinical Investigator…
|
04/15/2025
Update on the State of Vaccines for Melanoma
Introduction Scientists have recently advanced a strategy to send human cells instructions to generate an immune response against cancer. It…
|
02/06/2025
Genetic Testing Performed in Melanoma
A Q&A with an Investigator at the National Institutes of Health Dr. Michael Sargen M.D. is an Assistant Clinical Investigator…
|
12/27/2024
Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab
The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
|
|
10/17/2024
In Plain English: Update on Melanoma Vaccines, 2024
By Kim Margolin, M.D., FACP, FASCO Recap and background on tumor vaccines We last visited the topic of vaccines in…
|
|
Recent Posts
Sep. 09, 2025
Caring Through Loss: A Conversation on Bereavement
Sep. 05, 2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Sep. 04, 2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
Aug. 26, 2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
Aug. 26, 2025